The Guarantors of EQIPD Society is honored to receive a Sponsorship grant from Cohen Veterans Bioscience, a U.S.-based 501c3 public charity to support our critical work in driving quality and reproducibility of research. CVB has supported the EQIPD Consortium from its inception and is also a Founding Member of the Society. This funding will support critical programming and operations.
On October 10, 2022, #EQIPD will lead a discussion on how to help funders and grant applicants align on research rigor expectations and avoid funding of research of unknown quality. Objectives of the meeting are to: Review lessons learned from the US and German publicly funded programs that focused directly or indirectly on decision-enabling research…
The Research Transparency Tool was developed by the EQIPD Consortium Taskforce and implemented online with support from a SBIR award from the NIH: https://public-funding-tool.paasp.net/survey The tool creates a “snapshot” of the environment in which research is conducted and is meant to help funders and applicants align on relevant quality expectations. More information in the EQIPD…
EQIPD and our efforts to ” Unclog pipeline for new medicines” is mentioned in form of a brief article in NATURE CORRESPONDENCE. Click here to get to the article!
Members of the EQIPD consortium have identified and published 5 Domains for increasing rigour in animal experiments. The 5 Domains are published in Nature Methods and very well supplement the concept of the EQIPD quality system. Read about the EQIPD QS in our eLife publication The domains are summarised below and a more detailed overview…
The Guarantors of EQIPD and PAASP Network are delighted to announce the launch of a joint effort to promote the EQIPD framework, to deliver and to further develop the EQIPD Quality System. We very much look forward to this next stage in the EQIPD journey.
The “Guarantors of EQIPD” officially announced their launch with a public press release. The society is registered since December 2021 and became fully operational now. Read the press release here.